Trial Profile

First in man, randomized, double-blind, placebo-controlled, phase I trial assessing INF904 in complement-mediated, chronic autoimmune and inflammatory diseases

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Izicopan (Primary)
Indications Autoimmune disorders; Inflammation
Focus Adverse reactions; First in man
Sponsors InflaRx

Most Recent Events

04 May 2026 Results presented in the InflaRx media release.
04 Jan 2024 According to InflaRx media release, InflaRx will host a conference call to provide more details about the announced topline results of the MAD part of this study.
04 Jan 2024 Topline results (n=24 from the multiple ascending dose part) presented in the InflaRx Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com